Coya Therapeutics Q3 Revenue Down 12% YoY, FDA Accepts ALS Treatment IND.
ByAinvest
Wednesday, Nov 12, 2025 8:09 am ET1min read
COYA--
• Coya Therapeutics reports Q3 financial results • FDA accepts IND application for COYA 302 for ALS treatment • Received $4.2 million from Dr. Reddy's Laboratories • Published study linking inflammation to Parkinson's progression • Announced FDA acceptance of IND application for COYA 302 • Coya Therapeutics focuses on developing biologics for neurodegenerative disorders • Company provides corporate update and announces financial results • Coya Therapeutics is a clinical-stage biotechnology company based in Houston, TX
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet